Prognostic Factors in Non-Small Cell Lung Carcinoma
DOI:
https://doi.org/10.5644/Radovi.396Keywords:
NSCLC (Non-small Cell Lung Cancer), performans status, stage, LDH, leucocytosisAbstract
In recent years, a group of new prognostic factors have been added to the list of well-known clinical prognostic factors of non-small cell lung cancer (NSCLC). Among these are: mutation in K-ras oncogene, abnormal p53 proteins as result mutations on p53 tumor suppressor gene, the presence of N-CAM expression as measured by Mab immunostaining, elevated serum levels of neuron specific enolase (NSE) etc.
Today in B&H, these biomarkers not yet fine their place in every day clinical praxis. That is reason why we cannot speak about their prognostic significance on our clinical material.
Our positive prognostic factors that are significant for the treatment of patients with NSCLC are:
Stage I - IIIa, performance status <2 (ECOG), and age <60 - for resectable NSCLC and Stage IIIb, performance status <2 (ECOG), age <70 and loss body mass up to 55kg – for local advance NSCLC. Elevate of serum level of LDH and leucocytosis in this stage of NSCLC is result: extent of disease, metastatic disease and bad final issue.
References
Edinburgh Lung Cancer Group. Patient presenting with lung cancer in South East Scotland. Thorax 1987:42:853.
Bignall JR, Martin M, Smithers DW. Survival in 6086 cases of bronchial carcinoma. Lancet 1967; i: 1067.
Feld R, Rubinstein LV, Weisenberger TH and the Lung Cancer Study Group. Sites of recurrence in resected stage I non-small cell lung cancer: a guide for future studies. J Clin Oncol 1984; 2:1352—1358.
Yesner R. Pathogenesis and pathology. In: Matthay RA, editor. Clinics in chest medicine, vol 14. Philadelphia, PA: Saunders 1993; 17-30.
Lung-cancer, stageing and prognosis. Updated;www.cancerlineUK.net March 2002.
Movsas B, Scott C, Sause W et al. The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality adjusted survival analysis of radiation therapy oncology group (RTOG) chemoratiation studies. IntJ Radiat Oncol Biol Phys 1999; 45: 1143-1149.
Feld R, Borges M, Giner V et al. Prognostic factors in non-small cell lung cancer. Lung Cancer 1994; 1 l:Suppl. 3,19-23.
Meyer JA. The concept and significance of growt rates in human pulmonary tumors. An Thorac Surg 1972; 14:309. 1983.
Strauss MJ. Growth characteristics of lung cancer. In: Strauss MJ, ed. Lung Cancer: Clinical Diagnosis and Treatment. New York: Grune&Stratton, 1983.
Joseph WL, Morton DL, Adkins PC et al. Prognostic significance of tumour doubling time in evaluating operability in pulmonary metastatic disease. J Thorac Cardiovasc Surg 1971; 61:23.
Geddes DM. The natural hystoiy of lung cancer a review based on rates of tumour growth. BrJDis Chest 1979; 73:1.
Buccheri G. Tumor markers: clinical meaning and use. In: Brambilla C, Brambilla E, eds. Lung Tumors. New York, Marcel Dekker Ine., 1999; pp. 435-452.
Brechot JM, Chevret S, Nataf J, et al. Diagnostic and prognostic value of Cyfra 21-1 compared with other tumor markers in patients with non-small cell lung cancer: a prospeetive study of 116 patients. EurJ Cancer 1997;33:385-391.
Buccheri G, Ferrigno D. Prognostic value of stage grouping and TNM descriptors in lung cancer. Chest 2000; 117:1247-1255.
Gail MH, Eagan RT, Feld R, et al. Prognostic factors in patients with resected stage I non-small celi lung cancer. A report from the Lung Cancer Study Group. Cancer 1984; 54: 1802-1813.
Martini N, Burt H, Brains MS, et al. Survival after resection of stage II non small celll lung cancer. Ann Thorac Surg 1992; 54: 460-466.
Cangemi V, Volpino P, D Andrea N, et al. Local and/or distant recurrences in T1-2/N0-1 non small celi lung cancer. EurJ Cardiothorac Surg 1995; 9: 473-478.
Sawyer TE, Bonner JA, Gould PM, Deschamps C, Lange CM, Li H. Patients with stage I non-small cell lung carcinoma at postoperative risk for local recurrence, distant metastasis, and death: implications related to the design of clinical trials. Int J Radiol Oncol Biol Phys 1999; 45: 315-321.
Harpole DH, Hemdon JE, Young WG, et al. Stage I non-small cell lung cancer. A multivariate analysis of treatment methods and pattem of recurrence. Cancer 1995; 76: 787-796.
Brechot JM, Chevret S, Charpentier MC, et al. Blood Vessel an lymphatic vessel invasion in resected non.small cell lung carcinoma. Correlation with TNM stage and disease free and overall survival. Cancer 1996; 78:2111-2118.
Ichinose Y, Yano T, Asoh H, et al. Prognostic factors obtained by a pathologic examination in completely resected non-small cell lung cancer. An analysis in each pathologic stage. J Thorac Cardiovascidar Surg 1995; 110: 601-605.
Cherrington JM, Strawn LM, Shavwer LK. New paradigms for the treatment of cancer: the role of antiangiogenesis agents. Adv Cancer Res 2000; 79: 1-38.
Fontanini G, Lucchi M, Vignati S, et al. Angiogenesis as prognostic indicator of survival in non-small cell lung carcinoma: a prospective study. J Natl Cancer Inst 1997; 89: 881-886.
Folkman J. Angiogenesis and angiogenesis inhibition: an overview. EXS 1997;79:1-8.
Vermeulen PB, Gasparini G, Fox SB, et al. Quantification of angiogenesis of solid human tumours: an intemational consensus on the methodology and criteria ofevaluation. EurJCancer 1996; 32A: 2474-2484.
Rodenhuis S, Van de Wetering ML, Mooi WJ, et al. Mutationa activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med 1987; 317: 929-935.
Rodenhuis S, Slebos RJ, Boot AJM, et al. Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res 1988; 48: 5738-5741.
Slebos RJ, Kibbelaar RE, Dalesio O, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990; 323: 561-565.
Mitsudomi T, Viallet J, Mulshine JL, et al. Mutation of Ras genes distinghuis a subset of non-small cell lung cancer cell lines. Oncogene 1991; 6: 1353-1362.
Salgia R, Skarin AT. Molecular abnormalities in lung cancer. J Clin Oncol 1993; 16: 1207-1217.
Mitsudomi T, Oyama T, Kusano, et al: Mutation of p53 gene as a predictor of poor prognosis in patients with non-small cell lung cancer. JNatl cancer Inst 1993; 85: 2018-2023.
Fukuyama Y, Mitsudomi T, Sugio K, et al. K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small cell lung cancer. BrJ Cancer 1997; 75: 1125-1130.
Niklinska W, Burzykowski T, Chyczewski L, et al. P53 gene mutation and protein expression in operable non-small cell lung cancer in Poland. Eur J Cancer Prev 2000; 9: 81-87.
Passlick B, Izbicki JR, Haussinger K, et al. Immunohistochemical detection of p53 protein is not associated with a poor prognosis in non-small cell lung cancer. J Thorac Cardiovascnlar Surg 1995; 109: 1205-1211.
Belinsky SA, Nikula KJ, Palmisano WA, et al. Aberrant methylation of pl6(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Nat Acad Sci USA 1998; 95: 11891-11896.
Laudanski J, Niklinska W, Burzykowski T, et al. Prognostic significance of p53 and bcl-2 abnormalities in operable nonsmall cell lung cancer. EurRespir 72001; 17: 660-666.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Bakir Mehić, Hasan Žutić, Zehra Dizdarević, Adnan Hadžismajlović, Jasenko Lomigorić
This work is licensed under a Creative Commons Attribution 4.0 International License.
